返回
ADRIATIC: When face value is enough
DOI:10.1016/j.medj.2024.10.004.png)
摘要
En 中文
The ADRIATIC(1) study marks a major advancement in limited-stage small cell lung cancer (LS-SCLC), showing that consolidation therapy with durvalumab after chemoradiation significantly improves overall survival (OS) and progression-free survival (PFS). This establishes durvalumab as the new standard of care for LS-SCLC.
Keyword:
CELL LUNG-CANCER
期刊
IF:
11.8
论文数:
789
被引数:
2.2K
机构
引用论文
Variation in the risk of onset of acute myocardial infarction during the menstrual cycle月经周期中急性心肌梗死发病风险的变化
Durvalumab plus platinum-etoposide versus platinum-etoposide in first-line treatment of extensive-stage small-cell lung cancer (CASPIAN): a randomised, controlled, open-label, phase 3 trial
LANCET
IF88.5
Durvalumab, with or without tremelimumab, plus platinum-etoposide in first-line treatment of extensive-stage small-cell lung cancer: 3-year overall survival update from CASPIANDurvalumab,联合或不联合tremelimumab,联合铂类依托泊苷一线治疗广泛期小细胞肺癌: 来自里海的3年总生存率更新
ESMO OPEN
IF8.3
没有更多内容

